Iranian Journal of Psychiatry and Behavioral Sciences

Published by: Kowsar
Uncorrected Proof scheduled for 13 (2)

ABCB1 Polymorphisms in High-Dose and Low-Dose Dependent Patients Under Methadone Maintenance Treatment in an Iranian Population

Seyed Vahdat Hamraz 1 , Seyed Abbas Mousavi ORCID 2 , * , Asghar Shayannia 3 and Mehdi Mirzaii 4
Authors Information
1 Student Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran
2 Center for Health Related Social and Behavioral Sciences Research Shahroud University of Medical Sciences, Shahroud, Iran
3 Department of Medical Biotechnology, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran
4 Department of Microbiology, School of Public Health, Shahroud University of Medical Sciences, Shahroud, Iran
Article information
  • Iranian Journal of Psychiatry and Behavioral Sciences: In Press (In Press); e90236
  • Published Online: June 9, 2019
  • Article Type: Original Article
  • Received: February 4, 2019
  • Revised: April 18, 2019
  • Accepted: May 14, 2019
  • DOI: 10.5812/ijpbs.90236

To Cite: Hamraz S V, Mousavi S A , Shayannia A, Mirzaii M . ABCB1 Polymorphisms in High-Dose and Low-Dose Dependent Patients Under Methadone Maintenance Treatment in an Iranian Population, Iran J Psychiatry Behav Sci. Online ahead of Print ; In Press(In Press):e90236. doi: 10.5812/ijpbs.90236.

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. UNODC. World drug report 2016. New York: United Nations; 2016.
  • 2. Mojtahedzadeh V, Razani N, Malekinejad M, Vazirian M, Shoaee S, Saberi Zafarghandi MB, et al. Injection drug use in Rural Iran: Integrating HIV prevention into Iran's rural primary health care system. AIDS Behav. 2008;12(4 Suppl):S7-12. doi: 10.1007/s10461-008-9408-y. [PubMed: 18521737].
  • 3. Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, et al. Global burden of disease attributable to illicit drug use and dependence: Findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1564-74. doi: 10.1016/S0140-6736(13)61530-5. [PubMed: 23993281].
  • 4. Anderson P. Global use of alcohol, drugs and tobacco. Drug Alcohol Rev. 2006;25(6):489-502. doi: 10.1080/09595230600944446. [PubMed: 17132569].
  • 5. De Maeyer J, Vanderplasschen W, Broekaert E. Exploratory study on drug users’ perspectives on quality of life: More than health-related quality of life? Soc Indic Res. 2008;90(1):107-26. doi: 10.1007/s11205-008-9315-7.
  • 6. Farrell M, Ward J, Mattick R, Hall W, Stimson GV, des Jarlais D, et al. Methadone maintenance treatment in opiate dependence: A review. BMJ. 1994;309(6960):997-1001. doi: 10.1136/bmj.309.6960.997. [PubMed: 7950725]. [PubMed Central: PMC2541312].
  • 7. World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence 2009. Geneva: Switzerland Google Scholar; 2015.
  • 8. Wilder CM, Hosta D, Winhusen T. Association of methadone dose with substance use and treatment retention in pregnant and postpartum women with opioid use disorder. J Subst Abuse Treat. 2017;80:33-6. doi: 10.1016/j.jsat.2017.06.005. [PubMed: 28755770].
  • 9. Buhler KM, Gine E, Echeverry-Alzate V, Calleja-Conde J, de Fonseca FR, Lopez-Moreno JA. Common single nucleotide variants underlying drug addiction: More than a decade of research. Addict Biol. 2015;20(5):845-71. doi: 10.1111/adb.12204. [PubMed: 25603899].
  • 10. Stingl J, Viviani R. Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. J Intern Med. 2015;277(2):167-77. doi: 10.1111/joim.12317. [PubMed: 25297512].
  • 11. Wilkens S. Structure and mechanism of ABC transporters. F1000Prime Rep. 2015;7:14. doi: 10.12703/P7-14. [PubMed: 25750732]. [PubMed Central: PMC4338842].
  • 12. Pontual Y, Pacheco VSS, Monteiro SP, Quintana MSB, Costa MJM, Rolla VC, et al. ABCB1 gene polymorphism associated with clinical factors can predict drug-resistant tuberculosis. Clin Sci (Lond). 2017;131(15):1831-40. doi: 10.1042/CS20170277. [PubMed: 28572401].
  • 13. Bauer M, Wulkersdorfer B, Karch R, Philippe C, Jager W, Stanek J, et al. Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[(11) C]verapamil in elderly vs. young subjects. Br J Clin Pharmacol. 2017;83(9):1991-9. doi: 10.1111/bcp.13301. [PubMed: 28401570]. [PubMed Central: PMC5555869].
  • 14. Romermann K, Fedrowitz M, Hampel P, Kaczmarek E, Tollner K, Erker T, et al. Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain. Neuropharmacology. 2017;117:182-94. doi: 10.1016/j.neuropharm.2017.02.006. [PubMed: 28192112].
  • 15. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 2003;13(8):481-94. doi: 10.1097/01.fpc.0000054113.14659.b9. [PubMed: 12893986].
  • 16. Gregers J, Green H, Christensen IJ, Dalhoff K, Schroeder H, Carlsen N, et al. Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2015;15(4):372-9. doi: 10.1038/tpj.2014.81. [PubMed: 25582575]. [PubMed Central: PMC4762905].
  • 17. Cranford JA, Boyd CJ, McCabe S. Prevalence and correlates of recovery from drug dependence. Drug Alcohol Depend. 2017;171. e47. doi: 10.1016/j.drugalcdep.2016.08.142.
  • 18. McLinden T, Moodie EEM, Hamelin AM, Harper S, Rossi C, Walmsley SL, et al. Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis. Drug Alcohol Depend. 2018;185:374-80. doi: 10.1016/j.drugalcdep.2017.12.031. [PubMed: 29544189].
  • 19. Breitenstein B, Bruckl TM, Ising M, Muller-Myhsok B, Holsboer F, Czamara D. ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2015;168B(4):274-83. doi: 10.1002/ajmg.b.32309. [PubMed: 25847751].
  • 20. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75(1):13-33. doi: 10.1016/j.clpt.2003.09.012. [PubMed: 14749689].
  • 21. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001;69(3):169-74. doi: 10.1067/mcp.2001.114164. [PubMed: 11240981].
  • 22. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97(7):3473-8. doi: 10.1073/pnas.050585397. [PubMed: 10716719]. [PubMed Central: PMC16264].
  • 23. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70(2):189-99. doi: 10.1067/mcp.2001.117412. [PubMed: 11503014].
  • 24. Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther. 2006;80(6):682-90. doi: 10.1016/j.clpt.2006.09.011. [PubMed: 17178268].
  • 25. Lotsch J, Skarke C, Wieting J, Oertel BG, Schmidt H, Brockmoller J, et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther. 2006;79(1):72-89. doi: 10.1016/j.clpt.2005.09.010. [PubMed: 16413243].
  • 26. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics. 2005;15(10):693-704. doi: 10.1097/01.fpc.0000178311.02878.83. [PubMed: 16141795].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments